Patents Issued in June 18, 2024
-
Patent number: 12012394Abstract: The present invention generally relates to various compounds that are useful as ?-synuclein ligands. The invention further relates to methods of using these compounds and their radiolabeled analogs for the detection of synucleinopathies, including Parkinson's disease (PD).Type: GrantFiled: February 15, 2019Date of Patent: June 18, 2024Assignee: Washington UniversityInventors: Zhude Tu, Paul T. Kotzbauer, Xuyi Yue, Dhruva D. Dhavale
-
Patent number: 12012395Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.Type: GrantFiled: June 11, 2021Date of Patent: June 18, 2024Assignee: Edgewise Therapeutics, Inc.Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele
-
Patent number: 12012396Abstract: The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.Type: GrantFiled: August 2, 2023Date of Patent: June 18, 2024Assignee: Viracta Subsidiary, Inc.Inventors: Xiaohu Deng, Wanping Mai, Robert C. McRae, Biljana Nadjsombati
-
Patent number: 12012397Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.Type: GrantFiled: October 17, 2022Date of Patent: June 18, 2024Assignee: NodThera LimitedInventors: David Harrison, Alan Paul Watt, Mark G. Bock
-
Patent number: 12012398Abstract: Provided herein are compounds that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.Type: GrantFiled: July 11, 2022Date of Patent: June 18, 2024Assignee: NIDO BIOSCIENCES, INC.Inventors: Bakary-Barry Toure, Mark Andrew Gallop
-
Patent number: 12012399Abstract: Compounds of formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds or compositions in agriculture or horticulture for combating, preventing or controlling infestation of plants, harvested food crops, seeds or non-living materials by phytopathogenic microorganisms, in particular fungi.Type: GrantFiled: October 1, 2019Date of Patent: June 18, 2024Assignee: SYNGENTA PARTICIPATIONS AGInventors: Farhan Bou Hamdan, Matthias Weiss, Laura Quaranta
-
Patent number: 12012400Abstract: The present invention discloses a process for preparing compounds of Formula (I), particularly, a process manufacturing thereof on a multikilogram scale: wherein B, D, W, Z, R1, R2, and n are defined herein.Type: GrantFiled: February 18, 2022Date of Patent: June 18, 2024Assignee: NATIONAL HEALTH RESEARCH INSTITUTESInventor: Hsing-Pang Hsieh
-
Patent number: 12012401Abstract: Provided herein is a synthetic process for preparing a compound of Formula (1). The disclosure also provides useful intermediates and salts, amorphous and polymorph forms of the compound of Formula (1). These compounds are useful for various disease including cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, and osteoarthritis as well as Wnt-related diseases.Type: GrantFiled: March 18, 2021Date of Patent: June 18, 2024Assignee: BioSplice Therapeutics, Inc.Inventor: Sunil Kumar KC
-
Patent number: 12012402Abstract: Identified compounds demonstrate protein kinase inhibitory activity. More specifically, the compounds are demonstrated to inhibit receptor interacting kinase 2 (RIPK2) and/or Activin-like kinase 2 (ALK2). Compounds that are either dual RIPK2/ALK2 inhibitors or that preferentially inhibit RIPK2 or ALK2 could provide therapeutic benefit.Type: GrantFiled: October 13, 2021Date of Patent: June 18, 2024Assignees: UNIVERSITY OF HOUSTON SYSTEM, TRUSTEES OF TUFTS COLLEGEInventors: Gregory Cuny, Sameer Nikhar, Alexei Degterev
-
Patent number: 12012403Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:Type: GrantFiled: August 17, 2022Date of Patent: June 18, 2024Assignee: CHEMOCENTRYX, INC.Inventors: Penglie Zhang, Daniel R. Marshall, Howard S. Roth, Aubrie Harland
-
Patent number: 12012404Abstract: A class of pyrimidoheterocyclic compounds, and specifically disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 22, 2023Date of Patent: June 18, 2024Assignee: D3 Bio (Wuxi) Co., Ltd.Inventors: Yang Zhang, Wentao Wu, Jing Zhang, Jikui Sun, Yangyang Xu, Zhijian Chen, John Fenyu Jin, Shuhui Chen
-
Patent number: 12012405Abstract: A novel compound is provided. The novel compound is represented by General Formula (G1). Each of A1 and A2 independently represents a substituted or unsubstituted condensed aromatic ring, a substituted or unsubstituted condensed heteroaromatic ring, or a structure represented by Formula (Z-1) or (Z-2); and each of Z1 and Z2 independently has a structure represented by Formula (Z-1) or (Z-2), Each of X1 and X2 independently represents any one of an alkyl group, a cycloalkyl group, a substituted or unsubstituted cycloalkyl group having a bridge structure, and a trialkylsilyl group. Each of Ar1 and Ar2 independently represents a substituted or unsubstituted aromatic hydrocarbon group, and at least one of Ar1 and Ar2 includes the same substituent as X1. Each of R1 to R16 independently represents any one of hydrogen, an alkyl group, a substituted or unsubstituted cycloalkyl group, a trialkylsilyl group, and a substituted or unsubstituted aryl group.Type: GrantFiled: December 23, 2020Date of Patent: June 18, 2024Assignee: Semiconductor Energy Laboratory Co., Ltd.Inventors: Takuya Haruyama, Nobuharu Ohsawa, Satoshi Seo
-
Patent number: 12012406Abstract: Novel pyrido[4,3-e]pyrrolo[1,2-a]pyrimidine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrido[4,3-e]pyrrolo[1,2-a]pyrimidine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.Type: GrantFiled: January 11, 2024Date of Patent: June 18, 2024Assignee: KING FAISAL UNIVERSITYInventors: Michelyne Haroun, Christophe Tratrat
-
Patent number: 12012407Abstract: Novel pyrazolo[1,5-a]pyrido[4,3-e]pyrimidine-3-carboxylic acid compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrazolo[1,5-a]pyrido[4,3-e]pyrimidine-3-carboxylic acid compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.Type: GrantFiled: January 31, 2024Date of Patent: June 18, 2024Assignee: KING FAISAL UNIVERSITYInventors: Christophe Tratrat, Michelyne Haroun
-
Patent number: 12012408Abstract: The present disclosure relates to novel compound of Formula I, (I) or a pharmaceutically acceptable salt or solvate thereof; wherein Ra, Rb, Rc, Rd, ring A and ring B are as defined herein, pharmaceutical compositions containing same and methods for the treatment of cancer using same.Type: GrantFiled: June 21, 2019Date of Patent: June 18, 2024Assignee: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITYInventors: Moulay A Alaoui-Jamali, Krikor Bijian, Dominik Wernic
-
Patent number: 12012409Abstract: The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.Type: GrantFiled: January 14, 2021Date of Patent: June 18, 2024Assignee: Incyte CorporationInventors: Jeremy Roach, Artem Shvartsbart, Michael Witten, Wenqing Yao
-
Patent number: 12012410Abstract: A prophylactic or therapeutic agent for spinal muscular atrophy according to the present invention includes a compound represented by the formula (I) or a salt thereof: the variables are described herein.Type: GrantFiled: June 27, 2019Date of Patent: June 18, 2024Assignee: REBORNA BIOSCIENCES, INC.Inventors: Koji Fuji, Takeshi Yamasaki, Shunya Suzuki, Koji Ono, Hiroki Takahagi
-
Patent number: 12012411Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: November 30, 2021Date of Patent: June 18, 2024Assignee: Katholieke Universiteit LeuvenInventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Michael McNaughton, Arnaud Marchand, Johan Neyts, Wim Smets, Mohamed Koukni
-
Patent number: 12012412Abstract: The present disclosure provides solid forms of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, and methods of preparing and using the same.Type: GrantFiled: December 16, 2022Date of Patent: June 18, 2024Assignee: Pfizer Inc.Inventors: Caroline Yvette Proulx-Lafrance, John C. Amedio, Jr., Erika Volckova
-
Patent number: 12012413Abstract: Provided herein are methods of treating painful diabetic peripheral neuropathy, such as advanced painful DPN, in a patient by administering to the patient an effective amount of NYX-2925 or a pharmaceutically acceptable salt thereof. Also provided are crystalline forms of 3-hydroxy-2-(5-isobutyryl-1-oxo-2,5-diazaspiro[3,4]octan-2-yl)butanamide.Type: GrantFiled: November 10, 2020Date of Patent: June 18, 2024Assignee: Tenacia Biotechnology (Hong Kong) Co., LimitedInventors: M. Amin Khan, Mohsen Arghavani, Phil Bauer, Eduardo Mar
-
Patent number: 12012414Abstract: Novel imidazo[1,5-a]pyrido[4,3-e]pyrimidine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The imidazo[1,5-a]pyrido[4,3-e]pyrimidine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.Type: GrantFiled: January 4, 2024Date of Patent: June 18, 2024Assignee: KING FAISAL UNIVERSITYInventors: Christophe Tratrat, Michelyne Haroun
-
Patent number: 12012415Abstract: The invention is directed to composition and methods for the diagnosis, treatment and prevention of various disorders including but not limited to cancer and neurological disorders. In particular, the invention is directed to compositions and methods for the inhibition of PC4.Type: GrantFiled: June 27, 2019Date of Patent: June 18, 2024Assignee: AscentGene, Inc.Inventor: Hui Ge
-
Patent number: 12012416Abstract: A method of improving skin health and condition comprising the application of select isohexides to the skin.Type: GrantFiled: April 25, 2022Date of Patent: June 18, 2024Assignee: Sytheon LtdInventor: Ratan K Chaudhuri
-
Patent number: 12012417Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease caused by a viral infection: (I) wherein R1, R2, R3, A, L, m, n, p and q are as defined herein.Type: GrantFiled: June 18, 2019Date of Patent: June 18, 2024Assignee: NOVARTIS AGInventors: Cyrille Kounde, Wei Lin Sandra Sim, Oliver Simon, Gang Wang, Hui Quan Yeo, Bryan K S Yeung, Fumiaki Yokokawa, Bin Zou
-
Patent number: 12012418Abstract: The present invention is generally directed towards compounds capable of binding the aryl hydrocarbon receptor and modulating its activity, methods of treating inflammatory conditions such as Crohn's disease using such compounds, and pharmaceutical compositions comprising such compounds. Also provided are methods of increasing levels of IL-22 in a subject and/or decreasing levels of IFN-? in a subject.Type: GrantFiled: July 7, 2022Date of Patent: June 18, 2024Assignee: Nogra Pharma LimitedInventors: Francesca Viti, Salvatore Bellinvia, Salvatore Demartis
-
Patent number: 12012419Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.Type: GrantFiled: September 27, 2019Date of Patent: June 18, 2024Assignee: Takeda Pharmaceutical Company LimitedInventors: Shinobu Sasaki, Yasutomi Asano, Hironobu Maezaki, Ayumu Sato
-
Patent number: 12012420Abstract: The present invention relates to novel solid forms of compound (I), [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate and pharmaceutical compositions comprising the solid forms thereof disclosed herein, which may be used as a TLR7 agonist, or for the treatment or prophylaxis of a viral disease in a patient relating to HBV infection or a disease caused by HBV infection.Type: GrantFiled: December 23, 2021Date of Patent: June 18, 2024Assignee: Hoffmann-La Roche, Inc.Inventors: Katja Grosse-Sender, Urs Schwitter, Frank Stowasser, Xuemei Wang, Jing Xiong
-
Patent number: 12012421Abstract: The present invention relates to novel solid forms of compound (I), [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate and pharmaceutical compositions comprising the solid forms thereof disclosed herein, which may be used as a TLR7 agonist, or for the treatment or prophylaxis of a viral disease in a patient relating to HBV infection or a disease caused by HBV infection.Type: GrantFiled: December 23, 2021Date of Patent: June 18, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Katja Grosse-Sender, Urs Schwitter, Frank Stowasser, Xuemei Wang, Jing Xiong
-
Patent number: 12012422Abstract: The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic lateral sclerosis (ALS).Type: GrantFiled: August 26, 2021Date of Patent: June 18, 2024Assignee: ALS THERAPY DEVELOPMENT INSTITUTEInventors: Matvey Lukashev, Alexei Pushechnikov, Peter Demin, Kyle Denton
-
Patent number: 12012423Abstract: A composition having the structure of formula I: [R—Ar—(COOH)2]x[Ar—(COOH)3]2-xM32+??(I) is provided where M is Mn, Cu, Co, Fe, Zn, Cd, Ni, or Pt; R is a bromine, nitro, a primary amine, C1-C4 alkyl secondary amine, C1-C4 alkyl oxy, Br—(C1-C4 alkyl), NO2—(C1-C4 alkyl), a mercaptan, and reaction products of any of the aforementioned with acyl chlorides of the formulas: CH3(CH2)mC(O)Cl, or CH3(CH(C1-C4 alkyl)CH2)mC(O)Cl, or CH3(CH2)m-Ph-(CH2)pC(O)Cl, where Ph is a C6 phenyl or C6 phenyl with one or more hydrogens replaced with F, C1-C4 fluoroalkyl, or C1-C4 perfluoroalkyl; m is independently in each occurrence an integer of 0 to 12 inclusive; p is an integer of 0 to 36 inclusive, to form an amide, a thioamide, or an ester; Ar is a 1,3,5-modified phenyl, and 1.4>x>0. A process of synthesis thereof and the use to chemically modify a gaseous reactant are also provided.Type: GrantFiled: September 30, 2022Date of Patent: June 18, 2024Assignee: The United States of America as Represented by the Secretary of the ArmyInventors: Gregory W. Peterson, Thomas H. Epps, III
-
Patent number: 12012424Abstract: A process is provided for the production of bis-choline tetrathiomolybdate, the process comprising reacting a choline salt with ammonium tetrathiomolybdate, wherein the choline salt is a hydroxide, acetate, or halide choline salt, wherein the process comprises: combining the choline salt with a first mixture of ammonium tetrathiomolybdate in water, wherein a molar excess of choline salt to ammonium tetrathiomolybdate is used, for a first reaction period to provide a first reaction mixture; subjecting the first reaction mixture to a reduced pressure for a second reaction period to provide a second reaction mixture; and, isolating bis-choline tetrathiomolybdate from the second reaction mixture, wherein isolating bis-choline tetrathiomolybdate comprises adding ethanol to the second reaction mixture.Type: GrantFiled: February 15, 2019Date of Patent: June 18, 2024Assignee: Alexion Pharmaceuticals, Inc.Inventors: Johan Anders Wennerberg, Hans Roger Marcus Mårtensson
-
Patent number: 12012425Abstract: A functionalized fibrous hierarchical zeolite includes a framework comprising aluminum atoms, silicon atoms, and oxygen atoms, the framework further comprising a plurality of micropores and a plurality of mesopores. A plurality of nanoparticles comprising nickel are immobilized on the framework.Type: GrantFiled: August 26, 2021Date of Patent: June 18, 2024Assignees: King Abdullah University of Science and Technology, Saudi Arabian Oil CompanyInventors: Robert Peter Hodgkins, Omer Refa Koseoglu, Jean-Marie Maurice Basset, Kuo-Wei Huang, Anissa Bendjeriou-Sedjerari, Sathiyamoorthy Murugesan, Moussab Harb, Manoj Kumar Gangwar
-
Patent number: 12012426Abstract: The present invention relates to a transition metal complex having a PNNP4 ligand, which is easy to manufacture and handle and is relatively inexpensively available, and a method for manufacturing the same, as well as a method using this transition metal complex as a catalyst for hydrogenation reduction of ketones, esters and amides to manufacture corresponding alcohols, aldehydes, hemiacetals and hemiaminals, a method using this transition metal complex as a catalyst for oxidation of alcohols, hemiacetals and hemiaminals to manufacture corresponding carbonyl compounds, and a method using this transition metal complex as a catalyst for dehydrogenation condensation between alcohols and amines to manufacture alkylamines.Type: GrantFiled: March 13, 2023Date of Patent: June 18, 2024Assignee: Takasago International CorporationInventor: Shigeru Funane
-
Patent number: 12012427Abstract: Present invention relates to stable Fmoc protected Morpholino monomers and corresponding oligonucleotides (PMO) and efficient synthesis of the same involving chlorophosphoramidate and H-Phosphonate chemistry. Successful syntheses of the oligonucleotide with higher yield and lesser time have been accomplished employing solid phase synthesis and easy deprotection of Fmoc group with Piperidine.Type: GrantFiled: October 30, 2020Date of Patent: June 18, 2024Assignee: INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCEInventors: Surajit Sinha, Jayanta Kundu, Ujjwal Ghosh
-
Patent number: 12012428Abstract: The present invention relates to a method for preparing an activated lignin composition. In addition, the present invention also relates to a method for further processing the thus activated lignin composition in a method for preparing a lignin-phenol formaldehyde resin. Such a lignin-phenol formaldehyde resin can be used in the manufacturing of laminates by replacing the traditional synthetic phenol formaldehyde resin.Type: GrantFiled: April 16, 2018Date of Patent: June 18, 2024Assignee: TRESPA INTERNATIONAL B.V.Inventors: Andrew Sidney Jobber, Luca Ferrari, Kim Mechtilda Ferdinand Helwegen, Somayeh Kazemi, Atte Ilari Virtanen
-
Patent number: 12012429Abstract: The present invention provides novel and improved processes for treating a lignocellulosic biomass or technical lignin using ionic liquids to obtain lignin breakdown products and polysaccharide biomass components. Recycling of ionic liquids can be included in the methods of the invention.Type: GrantFiled: March 2, 2021Date of Patent: June 18, 2024Assignee: National Technology & Engineering Solutions of Sandia, LLCInventors: Noppadon Sathitsuksanoh, Ning Sun, Jian Shi, Anthe George, Manali Sawant, Seema Singh, Blake Simmons
-
Patent number: 12012430Abstract: The present disclosure relates to a method for preparing liquid maltitol and liquid polyols from a raffinate including maltitol. The method comprises the following steps: obtaining a hydrogenated liquid by hydrogenating a pre-treated raffinate including maltitol, obtaining a post-treated liquid by post-treatment of the hydrogenated liquid to remove impurities, obtaining a dilute liquid and a concentrated maltitol solution by membrane-separation of the post-treated liquid, and using the dilute liquid as the liquid polyols, and obtaining the liquid maltitol by mixing the concentrated maltitol solution with a prepared maltitol solution with a maltitol content of over 50%, wherein the liquid maltitol has a maltitol content greater than or equal to 50% and meets a standard. Before the membrane separation process, the present disclosure reduces the reducing sugar content in the liquid by hydrogenation to lower the risk of yellowing during the process and to improve the quality of the final product.Type: GrantFiled: September 18, 2023Date of Patent: June 18, 2024Assignee: ZHEJIANG HUAKANG PHARMACEUTICAL CO., LTD.Inventors: Yanhui Yao, Xinfeng Han, Fuan Wan, Hang Yue, Weixing Shen, Haojun Dai, Mingqian Yang, Mian Li
-
Patent number: 12012431Abstract: The present disclosure generally describes methods of preparing 1?-cyano nucleosides, such as a compound of Formula (I). For example, the compound of Formula (I) can be prepared from a compound of Formula (II-a) in a flow reactor.Type: GrantFiled: February 10, 2023Date of Patent: June 18, 2024Assignee: Gilead Sciences, Inc.Inventor: Sankar Mohan
-
Patent number: 12012432Abstract: A nucleic acid complex includes a single-stranded nucleic acid and a cross-linked double-stranded nucleic acid including the first nucleic acid strand linked to at least one of the 5? end and the 3? end of the single-stranded nucleic acid and the second nucleic acid strand including a base sequence that is completely or sufficiently complementary to the first nucleic acid strand.Type: GrantFiled: August 17, 2020Date of Patent: June 18, 2024Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Yasuo Komatsu, Yu Hirano, Yasuhiro Mie
-
Patent number: 12012433Abstract: Described herein are methods for the expression and purification of Cas13a and methods for detecting target RNA using Cas13a.Type: GrantFiled: February 25, 2021Date of Patent: June 18, 2024Assignee: INTEGRATED DNA TECHNOLOGIES INC.Inventors: Sarah Franz Beaudoin, Michael Allen Collingwood, Christopher Anthony Vakulskas, Mark Aaron Behlke
-
Patent number: 12012434Abstract: The present disclosure relates to a non-naturally occurring microorganism that includes a gene encoding a MucK transporter protein, where the microorganism is capable of catabolizing terephthalic acid (TPA). In some embodiments of the present disclosure, the gene encoding the MucK transporter protein may contain at least one mutation, relative to a reference gene encoding a reference MucK transporter protein.Type: GrantFiled: September 13, 2021Date of Patent: June 18, 2024Assignees: Alliance for Sustainable Energy, LLC, University of Georgia Research Foundation, Inc.Inventors: Christopher W. Johnson, Gregg Tyler Beckham, Isabel Pardo Mendoza, Ellen Lee Neidle
-
Patent number: 12012435Abstract: Polypeptides comprising a FimH lectin domain comprising an amino acid mutation that causes the FimH lectin domain to be in the low affinity conformation for mannose are described. Pharmaceutical compositions which comprise such polypeptides and methods of stimulating an immune response in a subject in need thereof by administration of the polypeptide are further described.Type: GrantFiled: July 26, 2022Date of Patent: June 18, 2024Assignee: JANSSEN PHARMACEUTICALS, INC.Inventors: Jan Grijpstra, Marleen Eveline Weerdenburg, Jeroen Geurtsen, Cristhina Kellen Fae, Jakob Louris Feitsma
-
Patent number: 12012436Abstract: Provided herein are methods for treating a disease or disorder associated with mitochondrial dysfunction through ex vivo introduction of a nucleic acid molecule into hematopoietic stem and progenitor cells (HSPCs) followed by transplantation of the HSPCs into a subject in need of treatment. The nucleic acid molecule may include a functional human frataxin (hFXN) or may include a gene editing system that when transfected into the cells removes a trinucleotide extension mutation of endogenous hFXN.Type: GrantFiled: March 15, 2017Date of Patent: June 18, 2024Assignee: The Regents of the University of CaliforniaInventor: Stephanie Cherqui
-
Patent number: 12012437Abstract: Provided herein are methods for treating a disease or disorder associated with mitochondrial dysfunction through ex vivo introduction of a nucleic acid molecule into hematopoietic stem and progenitor cells (HSPCs) followed by transplantation of the HSPCs into a subject in need of treatment. The nucleic acid molecule may include a functional human frataxin (hFXN) or may include a gene editing system that when transfected into the cells removes a trinucleotide extension mutation of endogenous hFXN.Type: GrantFiled: September 24, 2021Date of Patent: June 18, 2024Assignee: The Regents of the University of CaliforniaInventor: Stephanie Cherqui
-
Patent number: 12012438Abstract: The invention provides Brachyury deletion mutant polypeptides, nucleic acids encoding the polypeptides, non-yeast vectors comprising the nucleic acids, non-yeast cells, and methods of use.Type: GrantFiled: June 14, 2021Date of Patent: June 18, 2024Assignee: The United States of America, as represented by the Secretary, Health and Human ServicesInventors: Jeffrey Schlom, Claudia M. Palena
-
Patent number: 12012439Abstract: There is described a nucleic acid molecule comprising a nucleotide sequence encoding a functional dystrophin protein. Also described is a vector, a host cell and a pharmaceutical composition comprising the nucleic acid molecule; use of the nucleic acid molecule in therapy, such as in the treatment of a muscular dystrophy; and a method of treating muscular dystrophy, the method comprising administering a therapeutically effective amount of the nucleic acid molecule to a patient suffering from a muscular dystrophy.Type: GrantFiled: June 21, 2023Date of Patent: June 18, 2024Assignee: Royal Holloway and Bedford New CollegeInventors: John George Dickson, Linda Popplewell
-
Patent number: 12012440Abstract: Peptide analogs of a ?-defensin have been developed that provide a biphasic effect in treating disseminated fungal disease and/or associated septic shock. These analogs are active at concentrations below those needed to provide a fungicidal effect, and function by initially mobilizing effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response. These ?-defensin analogs are protective at concentrations where naturally occurring ?-defensins have no apparent effect, and include a core set of structural and sequence features not found in native ?-defensins.Type: GrantFiled: June 25, 2021Date of Patent: June 18, 2024Assignee: The University of Southern CaliforniaInventors: Michael E. Selsted, Dat Q. Tran, Justin B. Schaal, Virginia Basso
-
Patent number: 12012441Abstract: Orthogonal IL-21 receptors and orthogonal IL-21 cytokines are described. The IL-21 receptor-cytokine pairs may include an orthogonal interleukin-21 receptor ? chain (“ortho-IL-21R?”) that has impaired binding to native interleukin-21 cytokine (“IL-21”) and an orthogonal IL-21 cytokine (“ortho-IL-21”) that has impaired binding to native IL-21R?, wherein the ortho-IL-21R? binds to the ortho-IL-21. The IL-21 receptor-cytokine pair may activate IL-21 signaling. Cells engineered to express the orthogonal IL-21 receptors are also described, as well as methods for using such cells for treatment of various diseases and disorders.Type: GrantFiled: April 20, 2023Date of Patent: June 18, 2024Assignee: Neptune Biosciences LLCInventors: Nigel Killeen, Oren Beske, Benedikt K. Vollrath, Sridhar Govindarajan
-
Patent number: 12012442Abstract: Disclosed herein is an activatable fusion protein that includes, in an N- to C-terminal direction, an albumin, a matrix metalloproteinase-cleavable linker, and an immunoadhesin which includes a cytotoxic T lymphocyte-associated antigen-4 (CTLA4) having an N-terminal extracellular domain and an IgG Fc region, wherein the albumin is released from the activatable fusion protein in the presence of a matrix metalloproteinase that cleaves the cleavable linker, so that the N-terminal extracellular domain of the CTLA4 binds to CD80 or CD86. Also disclosed herein is use of the activatable fusion protein for suppressing a T cell-dependent immune response.Type: GrantFiled: April 19, 2021Date of Patent: June 18, 2024Assignee: NATIONAL YANG MING CHIAO TUNG UNIVERSITYInventors: Shey-Cherng Tzou, Yu-Yuan Hsiao, Fu-Yao Jiang, Yan-Zhu Zhang, Chien-Yu Chou
-
Patent number: 12012443Abstract: Described herein are immunomodulatory fusion proteins containing an extracellular binding domain and an intracellular signaling domain, wherein binding of a target can generate a modulatory signal in a host cell, such as a T cell. Some immunomodulatory fusion proteins as described comprise a SIRP? extracellular component and hydrophobic and intracellular components comprising transmembrane and/or signaling domains of a CD28, respectively. Such fusion proteins are capable of delivering a positive or costimulatory signal in response to a binding event that in a natural setting would result in an inhibitory signal. Uses of immune cells expressing such immunomodulatory fusion proteins to treat certain diseases, such as cancer or infectious disease, are also described.Type: GrantFiled: February 3, 2021Date of Patent: June 18, 2024Assignee: Fred Hutchinson Cancer CenterInventors: Shannon K. Oda, Philip D. Greenberg, Thomas M. Schmitt